Luminespib(NVP-AUY922)
-
Molecular Structure
Detailed Description
NVP-AUY922 is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis and licensed to Novartis. It is currently in Phase II clinical trials. NVP-AUY922 is an inhibitor of heat shock protein 90 (Hsp90), which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. NVP-AUY922 has shown promising activity in preclinical testing against several different tumor types.